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ABSTRACT Ab42 has been found to associate rapidly to neuronal cells and is the primary constituent of senile plaques. In this
study we monitored the aggregation of Ab42 with living PC12 cells. Using photobleaching Fo¨rster resonance energy transfer, we
observed one set of aggregates that displayed colocalization and another that displayed energy transfer. Cell surface aggregates
were found to become resistant to potassium iodide (KI)-induced quenching. Exposed Ab42 regions were probed with three
monoclonal antibodies directed against the N-terminus, an internal sequence, and the C-terminus of Ab42. Two populations
of aggregates were revealed: one that bound all three antibodies, and one that bound all but the C-terminus antibody. Of interest,
using ﬂuorescent recovery after photobleaching, we observed no Ab42 exchange within either type of aggregate. These ﬁndings
offer what we believe is new insight into the conformations of Ab42 that accumulate on the surface of living cells. One confor-
mation is incapable of energy transfer, is sensitive to KI, and binds C-terminus-speciﬁc antibodies. The other conformation
increases in number over time, is capable of energy transfer, is quencher-resistant, and has a sequestered C-terminus. With
further studies to characterize Ab aggregation on live cells, the underlying mechanisms leading to Alzheimer’s disease may
be revealed.doi: 10.1016/j.bpj.2009.01.056INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurological
disorder resulting from the deposition of amyloid b (Ab)
peptide into amyloid deposits, the appearance of neurofibril-
lary tangles, and selective neuronal loss. The most abundant
forms of Ab are 40 and 42 amino acid residues long and
referred to as Ab40 and Ab42, respectively (1). Ab is
produced from sequential endoproteolytic cleavage of the
amyloid precursor protein (APP). Ab40 is the primary
product of proteolytic cleavage from APP (2), but it has
been shown that Ab40 displays relatively slow association
kinetics with neuronal cells, whereas Ab42 associates
rapidly with neuronal cells (3). Studies have shown that
Ab42 has a higher propensity to aggregate than Ab40
(2–5) and is the primary constituent of senile plaques (6,7).
Many Ab conformations have been proposed and charac-
terized as intermediates in the pathway to formation of the
amyloid fiber. Some of these structures include dimers,
trimers, pentamers, high-molecular-weight Ab-derived
diffusible ligands, protofibrils, and fibrils (8–13). However,
the mechanism underlying formation of Ab aggregates
within neuronal cells still remains unclear.
We previously established a versatile method for studying
Ab aggregation (3), in which Ab is fluorescently labeled at
the N-terminus and then added to live cells. This approach
allowed us to monitor the rate of association with cells as
well as their intrinsic aggregation rate (3). Here we sought
to monitor structural aspects of the aggregation of Ab42
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energy transfer (pbFRET), specific domain-directed mono-
clonal antibodies, and a fluorescence quencher, we identified
two distinct conformations of Ab42 that form with living
cells. Using fluorescent recovery after photobleaching
(FRAP), we also noted the absence of peptide unit exchange
within aggregates located on the cell surface.
MATERIALS AND METHODS
Peptide synthesis and puriﬁcation
Ab42 was prepared by solid-phase synthesis on a PS-3 peptide synthesizer
(Protein Technologies, Tucson, AZ) using Ala-PEG-PS resin (PerSeptive Bi-
osystems, Ramsey, MN). An active ester coupling procedure employing O-
(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl-uronium hexafluorophosphate
of 9-fluorenylmethoxycarbonyl amino acids was used. For fluorophore addi-
tion, before cleavage from the resin either Na-(9-Fluorenylmethoxycar-
bonyl)-N3-tetramethylrhodamine-(5-carbonyl)-L-lysine (TMR, F11830;
Molecular Probes, Eugene, OR) or 6-carboxyfluorescein (FAM, C0662;
Sigma, St. Louis, MO) were coupled to the N-terminus via a glycine linker.
The peptides were cleaved from the resin with a mixture of trifluoroacetic
acid, thioanisole, m-cresol, and ethanedithiol (81:13:1:5 v/v). After incuba-
tion for 45 min at 25C, the resin was removed by filtration. After incubation
for an additional 3 h at 25C, the volume was reduced and peptides were
precipitated and washed in cold ethyl ether. The crude peptides were dis-
solved in 6.5 M guanidine hydrochloride (pH 10) and purified by high-perfor-
mance liquid chromatography using a Superdex Tricorn 10/300 GL Peptide
column (Amersham Biosciences, Piscataway, NJ) with 30 mM NH4OH
running buffer. To maintain stock peptide solutions free from fibril seeds,
solutions were stored at pH 10 and 4C immediately after chromatographic
separation of monomeric peptides. These conditions were previously shown
to maintain the monomeric state (10,14,15). Peptide purity and identity was
confirmed with the use of both matrix-assisted laser desorption/ionization
mass spectrometry and amino acid analysis. Concentrations of stock peptide
solutions that were free of fibril seeds were determined by amino acid anal-
ysis and confirmed by either tyrosine absorbance (275 nm, 3 ¼ 1390 cm1
Ab Aggregates on PC12 Cells 4261M1), TMR absorbance (550 nm, 3 ¼ 92000 cm1 M1), or FAM absor-
bance (488 nm, 3 ¼ 87000 cm1 M1) for labeled peptides.
Cell culture
Cell lines were maintained in Dulbecco’s modified Eagle’s medium (nutrient
mixture F-12 1:1 (DMEM/F12), 12500; Gibco, Burlington, Ontario, Canada)
containing 10% fetal bovine serum (HyClone, Logan, UT) with 100 U/mL
penicillin and 100 mg/mL of streptomycin. To induce differentiation of
PC12 cells to resemble sympathetic neurons, the cells were plated at 2.2 
104 cells/cm2 in Lab-tech chambered coverglass chambers and suspended
in phenol red free DMEM/F12 (21041; Gibco) containing N2 supplement
and 10 ng/mL nerve growth factor. Cells were differentiated for 72 h before
media was replaced and peptide treatments were performed. Cells were main-
tained at 37C in a humidified incubator with 5% carbon dioxide.
Fluorimeter FRET measurements
The FAM-only sample was prepared using 10 mM unlabeled Ab42 and 10mM
FAM-Ab42, with pH 5 reduction using 2 mM HCl. The TMR-only sample was
prepared using 10 mM unlabeled Ab42 and 10mM TMR-Ab42, with pH 5
reduction using 2 mM HCl. The Mix sample was prepared using 10 mM
TMR-Ab42 and 10mM FAM-Ab42, with pH 5 reduction using 2 mM HCl.
Emission wavelength spectra were collected using 488 nm excitation on a PTI
fluorimeter with 3-nm slit widths after peptide incubation at 20C for 90 min.
pbFRET measurements
When an acceptor fluorophore is in close proximity to a donor fluorophore, the
photobleaching of that donor proceeds more slowly than in the absence of the
acceptor; this is the basis behind pbFRET (16,17). The two photobleaching
rates for the donor under the same conditions are used to calculate the FRET
efficiency (16,17). PC12 cells were treated with 1 mM unlabeled Ab42 and
1mM FAM-Ab42 (for the FAM-only sample) or 1 mM TMR-Ab42 and
1mM FAM-Ab42 (for the Mix sample) for 1, 6, 12, and 24 h. Fluorescent
images were taken with a Zeiss LSM 510 META confocal laser-scanning
microscope with a 40 water immersion objective and a 1.2 numerical aper-
ture. Images were initially collected using a 488 nm Argon laser at 2% power
with a band-pass (BP) filter 500–550 nm (FAM-only and Mix samples) and
543 nm HeNe laser at 75% power with a BP filter 565–615 nm (Mix samples).
For pbFRET data sets, l mode was selected for monitoring at spectral wave-
lengths 527 nm and 591 nm with 458 nm and 488 nm Argon laser lines at
45% power for 527 s with 60 collected frames. At least two aggregate regions
were selected per cell from fields of view with at least 20 cells from three inde-
pendent experiments performed in duplicate, resulting in >300 aggregates
analyzed per condition. Fluorescent decay was calculated over the time series
using ImageJ version 1.37v. Single exponential curve fits and graphs were
prepared using Microcal Origin 7.0 SR4 with the following equation:
y ¼ Aeðx=tÞ;
where A is the amplitude of the curve and t is the time constant. The transfer
efficiency (E) was calculated using the following equation:
E ¼ 1  ðtFam=tMixÞ;
where tFam is the time constant calculated for the FAM-Ab42-only sample
at a given treatment time, and tMix is the time constant calculated for the
Mix sample at the same treatment time. Histograms and bar graphs were
prepared using Microsoft Excel. The displayed images represent a single
cross section through the center of the cells.
Immunoblotting
Ab42 (concentrations 500 ng to 10 pg) was spotted onto polyvinylidene
fluoride (PVDF) membranes. Membranes were blocked in 5% (w/v)
powdered milk, 0.05% (v/v) Tween 20 in PBS for 2 h, followed by 1-h treat-ment with 2 mg/mL of either 6E10 antibody (A1474; Sigma), 4G8 antibody
(MAB1561; Chemicon, Billerica, MA), or 12F4 antibody (05-831; Upstate).
For detection, 1:5000 dilution of secondary goat anti-rabbit peroxidase conju-
gated antibody (401353; Calbiochem, La Jolla, CA) was used and visualized
with enhanced chemiluminescence reagent plus (RPN2132; Amersham,
Buckinghamshire, UK). Exposed films were developed for 10 min.
Immunostaining Ab on the surface
of live PC12 cells
PC12 cells treated with unlabeled Ab42 (2 mM) for 2 h at 37C were washed
once with cold blocking solution containing 1% BSA (Fisher Scientific,
Nepean, ON) and 0.1% sodium azide in phosphate-buffered saline without
calcium and magnesium (D-PBS), followed by incubation for 15 min at
4C in cold blocking solution. The N-terminus region was detected by
10 mg/mL of 6E10 antibody (A1474; Sigma), an internal peptide sequence
was detected by 10 mg/mL of 4G8 antibody (MAB1561; Chemicon), and
the C-terminus region was detected using 10 mL/mL of 12F4 antibody
(05-831; Upstate). Cells were incubated for 25 min with primary antibody
followed by washing with cold blocking solution, and for 25 min with
10 mg/mL secondary antibody, rabbit anti-mouse Alexa fluor 488 conjugated
antibody (A-11059; Gibco-Invitrogen) at 4C in cold blocking solution.
After antibody removal and washing with cold blocking solution, cells
were mechanically detached with D-PBS. Collected cells were centrifuged
(200  g for 1 min) and resuspended in cold flow buffer containing
5 mM EDTA and 1% BSA (Fisher Scientific, Nepean, ON) in D-PBS.
Samples were immediately analyzed with a FACS Calibur flow cytometer
(Becton Dickinson, Mississauga, ON). Alexa fluor 488 fluorescence was
detected, with 2.5  104 live events collected per sample with a 100–300
events/s flow rate. Cell viability was assessed and gated with exclusion of
25 mg/mL 7-Aminoactinomycin D (7-AAD) treatment for 5 min. Data
collection and analysis were performed using Cell Quest version 3.3, and
figures were created using WinMDI version 2.8 software.
Potassium iodide quenching
PC12 cells were treated with 2 mM TMR-Ab42 for 1, 6, 12, and 24 h. Media
were removed and replaced with D-PBS, and fluorescent image stacks were
collected before and after 30-min treatment with 300 mM potassium iodide
using a Zeiss LSM 510 META confocal laser-scanning microscope. The
displayed images represent a single cross section through the center of the
cells and were prepared using ImageJ version 1.37v.
FRAP measurements
PC12 cells were treated with 2 mM FAM-Ab42 for 1, 6, 12, and 24 h. Two
initial images were collected using a 488 nm Argon laser at 2% power with
a BP filter (500–550 nm). Selected aggregate regions were photobleached
for 20 s using 458 nm and 488 nm Argon laser lines at 50% power. Images
were then collected using a 488 nm Argon laser at 2% power, with 100
images acquired for total of 638 s. Fluorescence was calculated over the
time series using ImageJ version 1.37v. The graphs were prepared using
Microcal Origin 7.0 SR4 with an average of 10 photobleached regions
and 10 nonphotobleached regions, and all were normalized to the same
initial fluorescent value.
RESULTS
Colocalization and energy transfer
To study Ab on the surface of live cells, we synthesized and
fluorescently labeled Ab42. Of importance, synthesized Ab
was maintained in solution from synthesis to purification
and storage, as these conditions are known to significantlyBiophysical Journal 96(10) 4260–4267
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covalently attached either FAM or TMR to the N-terminus of
Ab via a flexible glycine linker to generate FAM-Ab42 or
TMR-Ab42, respectively. The N-terminus is highly acces-
sible (18,19), and it has been shown that attaching a fluores-
cent label does not alter its amyloidogenic properties
(3,10,20) or solubility behavior (21,22). FAM and TMR
fluorophores were selected because they do not selectively
partition into any particular subcellular organelle or microen-
vironment (23,24) and their fluorescence properties are ideal
for confocal microscopy (16,25).
We compared the effects of treating live differentiated
PC12 cells (which are derived from a pheochromocytoma
of the rat adrenal medulla) with FAM-Ab42 alone or in
combination with TMR-Ab42 (Mix). After 24-h treatments
with either FAM-Ab42 or Mix, confocal microscopy of
a plane within individual PC12 cells was imaged. The
distinct staining pattern of Ab42 was observed on the cell
body, neuritic extensions, and within the cell (Fig. 1).
Similar staining patterns were observed when imaging was
performed with lasers and filters specific for FAM (shown
in green, Fig. 1 A) and for TMR (shown in red, Fig. 1 B),with the merged image highlighting colocalization (shown
in yellow, Fig. 1 C). Using a Zeiss spectral META detector
and specific FAM lasers, we monitored the specific emission
wavelength for FAM (Fig. 1 D) and TMR (Fig. 1 E). High-
lighted in yellow (Fig. 1 F) are regions where strong energy
transfer between these fluorophores was detected. FAM- and
TMR-labeled Ab42 appeared to make an excellent donor/
acceptor FRET pair. In the Mix sample we observed quench-
ing of FAM emission and increased TMR fluorescence when
only FAM was excited (see Fig. S1 in the Supporting Mate-
rial). pbFRET was observed for specific aggregates (Fig. 1 g)
where the excited FAM transferred its energy to TMR,
reducing its photodegradation rate. Selecting two aggregates
that displayed colocalization (Fig. 1, A and B) and photo-
bleaching for 527 s, we observed that the first aggregate pho-
tobleached at a rate similar to that of FAM alone, as reflected
by similar time constants (Fig. 1 J). The second aggregate
photobleached much more slowly with a longer time
constant, indicating energy transfer (Fig. 1 K). Similar time
constants were observed for treatment of living PC12 cells
with FAM alone over various treatment times (Fig. 2). For
the Mix samples, we observed increasing average timeFIGURE 1 Colocalization and pbFRET aggregates of
Ab42 with live PC12 cells treated for 24 h. All images
were taken through the center of the cells. Scale bars are
10 mm. (A) Mix sample monitoring with a BP filter for
the total FAM signal. (B) Mix sample monitoring with
a BP filter for the total TMR signal. (C) Merged imaged
of FAM and TMR total signals. (D) Mix sample exciting
FAM and monitoring the initial FAM signal at a spectral
wavelength of 527 nm. (E) Mix sample exciting FAM
and monitoring the initial TMR signal at a spectral wave-
length of 591 nm. (F) Merge of initial FAM and TMR
signals. (G) Mix sample exciting FAM and monitoring
the final FAM signal at a spectral wavelength of 527 nm.
(H) Mix sample exciting FAM and monitoring the final
TMR signal at a spectral wavelength of 591 nm. (I) Merge
of final FAM and TMR signals after 527 s of bleaching. (J)
Fluorescent decay curve for Mix region 1 compared with
FAM-alone decay curve. (K) Fluorescent decay curve for
Mix region 2 compared with FAM-alone decay curve.
Biophysical Journal 96(10) 4260–4267
Ab Aggregates on PC12 Cells 4263FIGURE 2 Time constant and transfer efficiency aver-
ages calculated for Ab42 over time. The time constants
for FAM-Ab42 were similar for all treatments. Error bars
are indicated as the standard deviation from at least three
independent experiments. For each cell, two to five aggre-
gate regions were selected from fields of view, with at least
20 cells from three independent experiments performed in
duplicate, resulting in over 300 aggregates analyzed for
each Ab42 time point.constants with increasing treatment time (Fig. 2). Monitoring
aggregates on the cell body versus the cell neurite revealed
that the average transfer efficiency for the aggregates located
on the cell body after 24 h of treatment was similar to that for
aggregates on the neurites after only 6 h of treatment (Fig. 2).
However, the distribution of transfer efficiency for the
various time points seemed to indicate two key populations:
aggregates that have no energy transfer, and aggregates that
transfer energy to varying degrees (Fig. 3). The presence of
these two aggregate populations on the cell surface indicates
that there is a population of aggregates in which the peptide
units are closely packed to allow energy transfer, and another
aggregate population in which the peptide units are spaced
apart and incapable of energy transfer. A very different
distribution was observed when we compared aggregates
on the surface of living PC12 cells with internalized aggre-
gates (Fig. 4). The internalized aggregates were observed
to have an average transfer efficiency of 0.6, with most of
the observed aggregates allowing for energy transfer
(Fig. 4). This finding suggests that the process of internaliza-
tion causes increased compaction of the aggregates.
Accessible and restricted aggregates
To investigate which regions of Ab42 within the aggregates
were exposed, we treated live PC12 cells with unlabeled
Ab42 for 2 h, followed by treatment with one of three mono-
clonal mouse antibodies targeted to a specific region of
Ab42. Antibodies were added in high excess to PC12 cells
because their detection concentration was observed to vary
by dot blot analysis (Fig. S2). Using flow cytometry, we
also observed two key populations of aggregates: one that
stained with all three antibodies, and one that stained
primarily with the internal sequence and N-terminus-specific
antibodies (Fig. 5). The exclusion of the C-terminus antibodyindicates that these aggregates may be more compact with
the C-termini buried and represent a smaller fraction of the
total number of observed events (Fig. 5). The population
that stained with the C-terminus antibody may correlate
with the population that is incapable of energy transfer, as
both observations are consistent with the larger fraction of
the total number of observed events.
To further assess the level of aggregate compaction, we
utilized potassium iodide (KI), which is a small molecule
quencher of fluorescence (26,27). After using KI to treat
aggregates that formed on the surface of PC12 cells, we
found that the majority of the aggregates were quenched
(Fig. 6). With increasing exposure time of the cells to
Ab42, there were visually more KI resistant aggregates on
the surface of living PC12 cells (Fig. 6). However, a distribu-
tion of surface aggregates was observed with KI-sensitive
aggregates and KI-resistant aggregates, even for the 24-h
Ab42 treatment (Fig. 6).
Nonexchanging aggregates
We monitored the peptide unit exchange rate within an
aggregate using photobleaching (i.e., the rate of FRAP indi-
cates unbleached peptides exchanging for photobleached
peptides within an aggregate). Over all the treatment times
during which FAM-Ab42 was added to PC12 cells, no
recovery from photobleaching was observed (Fig. 7). The
global fluorescence within the aggregates did not recover
from the photobleaching event (Fig. 7). This may indicate
that very few peptide units exchange within the aggregates,
or that the period for peptide exchange is much greater
than the period monitored. Alternatively, these results may
indicate that once the peptide associates into an aggregate,
it is locked into place, allowing for further deposition of
peptide units into this aggregate.Biophysical Journal 96(10) 4260–4267
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To model AD at the cellular and molecular levels, many
investigators have used dyes, radioactive Ab, and antibodies
to study the interactions of Ab with cell cultures (28–36).
However, these approaches carry certain limitations,
including the inability to easily monitor aggregation progres-
sion in real time on live cells. To overcome such limitations,
we developed a versatile approach that involves treating live
cells with Ab that has been N-terminally linked with fluoro-
phores. Using this approach, we previously showed a correla-
tion between the aggregation propensity of Alzheimer
amyloid-b peptides and their cell surface association kinetics
FIGURE 4 Comparison of transfer efficiencies for cell
surface versus internalized Ab42 aggregates. Three inde-
pendent experiments were performed in duplicate, yielding
fields of view with at least 20 cells. For each cell, 2–5
aggregate regions were selected, resulting in ~300 surface
aggregates and 100 internalized aggregates analyzed for
each 24-h Ab42 treatment.
FIGURE 3 Transfer efficiency histograms obtained for
all Ab42 time samples. For each cell, 2–5 aggregate
regions were selected from fields of view, with at least
20 cells from three independent experiments performed
in duplicate, resulting in over 300 aggregates analyzed
for each Ab42 time point.
Biophysical Journal 96(10) 4260–4267
Ab Aggregates on PC12 Cells 4265FIGURE 5 Accessibility of aggregates to region-specific
monoclonal antibodies. The Ab42 sequence is indicated
with box regions specifying the recognition regions for
each antibody. Flow cytometry histograms indicate signals
from untreated cells (thick black line) and specific anti-
body-treated cells (solid gray area).with neuronal cells (3). In addition, our findings revealed
a punctate staining pattern that is similar to images collected
with antibodies directed specifically against oligomeric
structural forms of Ab (33,34). Furthermore, our technique
allows images to be obtained with live cells throughout the
progression of Ab aggregation and its multitude of interme-
diate states.
In this study, we adapted our fluorescence imaging tech-
nique to further understand how Ab42 aggregates during
its interaction with living cells. Treating live PC12 cells
with a combination of FAM-Ab42 and TMR-Ab42, we
observed colocalization of fluorescent signals (Fig. 1 C),
energy transfer (Fig. 1 F), and pbFRET (Fig. 1 I). In addition,
our transfer efficiency analyses showed that there were two
major aggregate populations at all of the analyzed treatmenttimes (Fig. 3), and these populations could be distinguished
based on whether they were or were not transferring energy.
After comparing the histograms from cell surface versus
internalized aggregates (Fig. 4), we observed that the latter
were more prone to transfer energy. This finding may indi-
cate that the more compact aggregates that are capable of
energy transfer are internalized, or that the act of cell inter-
nalization allows for aggregate compaction and greater
energy transfer. These results indicate the existence of two
aggregate conformations that differ in their level of compac-
tion for energy transfer.
To further investigate the compaction of the cell surface
aggregates, we probed them with KI. This set of experiments
revealed two populations that were either sensitive or resis-
tant to KI, and showed that the resistance to KI increasedFIGURE 6 Susceptibility of Ab42 aggregates to small
molecular quencher KI over time. All images were taken
through the center of the cells with 10 mm scale bars.
The length of time the cells were exposed to Ab42 is indi-
cated on the left.
Biophysical Journal 96(10) 4260–4267
4266 Bateman and ChakrabarttyFIGURE 7 Peptide exchange within Ab42 aggregates is
absent over all treatment times. The normalized fluorescent
signal was plotted versus time for each average fluorescent
recovery experiment. The bleached sample slopes (black
box) are approximately equal to the nonbleached sample
slopes (open gray circle), indicating lack of fluorescent
recovery.over the time that PC12 cells were treated (Fig. 6). To deter-
mine which regions of the surface aggregates were exposed,
we used flow cytometry to test whether monoclonal anti-
bodies specific for one of three Ab42 regions could stain
the aggregates. Again, we uncovered two key aggregate pop-
ulations (Fig. 5): a large population that stained with all three
domain-specific antibodies, and a small population that did
not stain with the C-terminus-specific antibody. These exper-
iments were conducted with an extreme excess of antibodies,
as varied Ab42 detection concentration was observed
(Fig. S2). This observed variation could have been due to
either the antibody detection limit or the availability of the
exposed region against which the antibody was directed.
Strikingly, we observed the absence of FRAP with all of
the varied Ab42 treatment times (Fig. 7). These results
may indicate that once the aggregation seeds have formed
on the surface of cells, the addition of peptide units is essen-
tially irreversible. However, it may also be possible that the
rate of exchange for individual peptide units is on the order
of hours and hence would not be detected with our method.
Alternatively, the number of peptide units capable of
exchange within an aggregate may be extremely small, and
even though the units may exchange, the actual number
may be below our detection limit.
These findings offer what we believe is new insight into
the conformations of Ab42 accumulating on the surface of
living cells. With further live cell studies and continued char-
acterization of the aggregation events, the underlying mech-
anisms leading to Alzheimer’s disease may be elucidated,
allowing for the development of novel therapeutics against
specific conformational targets.Biophysical Journal 96(10) 4260–4267SUPPORTING MATERIAL
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